CNTX · Insider Trading
Context Therapeutics Inc. Common Stock
Every open-market purchase and sale reported by CNTX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-26 | Linda West | Director | A | +45,000 deriv. | — |
| 2026-06-26 | Andy Pasternak | Director | A | +45,000 deriv. | — |
| 2026-06-26 | Luke Nathaniel Walker | Director | A | +45,000 deriv. | — |
| 2026-06-26 | Philip W. Kantoff | Director | A | +45,000 deriv. | — |
| 2026-06-26 | Karen L. Smith | Director | A | +45,000 deriv. | — |
| 2026-06-26 | Jennifer Evans Stacey | Director | A | +45,000 deriv. | — |
| 2026-02-23 | Martin A. Lehr | Chief Executive Officer | A | +815,000 deriv. | — |
| 2026-02-23 | Jennifer Lynn Minai-Azary | Chief Financial Officer | A | +275,000 deriv. | — |
| 2026-02-23 | Alex C. Levit | Chief Legal Officer, Corp. Sec | A | +270,000 deriv. | — |
| 2026-02-23 | Karen Deborah Chagin | Chief Medical Officer | A | +290,000 deriv. | — |
| 2025-06-12 | Luke Nathaniel Walker | Director | A | +123,500 deriv. | — |
| 2025-06-12 | Karen L. Smith | Director | A | +123,500 deriv. | — |
| 2025-06-12 | Andy Pasternak | Director | A | +138,900 deriv. | — |
| 2025-06-12 | Jennifer Evans Stacey | Director | A | +123,500 deriv. | — |
| 2025-06-12 | Philip W. Kantoff | Director | A | +123,500 deriv. | — |
| 2025-06-12 | Linda West | Director | A | +123,500 deriv. | — |
| 2025-06-10 | Jennifer Lynn Minai-Azary | Chief Financial Officer | Buy | +40,010 | +$25.49K |
| 2025-06-10 | Martin A. Lehr | Chief Executive Officer | Buy | +100,000 | +$70.08K |
| 2025-06-10 | Alex C. Levit | Chief Legal Officer, Corp. Sec | Buy | +20,000 | +$11.52K |
| 2025-06-09 | Karen Deborah Chagin | Chief Medical Officer | A | +153,000 deriv. | — |
| 2025-02-14 | Martin A. Lehr | Chief Executive Officer | A | +802,700 deriv. | — |
| 2025-02-14 | Ullmann Claudio Dansky | Chief Medical Officer | A | +174,960 deriv. | — |
| 2025-02-14 | Jennifer Lynn Minai-Azary | Chief Financial Officer | A | +371,800 deriv. | — |
| 2025-02-14 | Alex C. Levit | Chief Legal Officer, Corp. Sec | A | +349,900 deriv. | — |
| 2025-01-14 | Andy Pasternak | Director | A | +20,685 deriv. | — |
| 2024-09-05 | Luke Nathaniel Walker | Director | A | +19,315 deriv. | — |
| 2024-09-05 | Karen L. Smith | Director | A | +19,315 deriv. | — |
| 2024-08-01 | Ullmann Claudio Dansky | Chief Medical Officer | A | +202,170 deriv. | — |
| 2024-06-14 | Jennifer Evans Stacey | Director | A | +25,000 deriv. | — |
| 2024-06-14 | Richard J Berman | Director | A | +50,000 deriv. | — |
| 2024-06-14 | Linda West | Director | A | +25,000 deriv. | — |
| 2024-06-14 | Philip W. Kantoff | Director | A | +25,000 deriv. | — |
| 2024-03-22 | Jennifer Lynn Minai-Azary | Chief Financial Officer | A | +160,115 deriv. | — |
| 2024-03-22 | Martin A. Lehr | Chief Executive Officer | A | +291,402 deriv. | — |
| 2024-03-22 | Alex C. Levit | Chief Legal Officer, Corp. Sec | A | +153,515 deriv. | — |
| 2023-05-31 | Jennifer Evans Stacey | Director | A | +25,000 deriv. | — |
| 2023-05-31 | Philip W. Kantoff | Director | A | +25,000 deriv. | — |
| 2023-05-31 | Linda West | Director | A | +25,000 deriv. | — |
| 2023-05-31 | Richard J Berman | Director | A | +50,000 deriv. | — |
| 2023-02-21 | Martin A. Lehr | Chief Executive Officer | Buy | +5,823 | +$4.90K |
| 2023-02-14 | Martin A. Lehr | Chief Executive Officer | A | +287,544 deriv. | — |
| 2023-02-14 | Alex C. Levit | Chief Legal Officer, Corp. Sec | A | +151,505 deriv. | — |
| 2023-02-14 | Jennifer Lynn Minai-Azary | Chief Financial Officer | A | +158,001 deriv. | — |
| 2023-02-13 | Martin A. Lehr | Chief Executive Officer | Buy | +5,606 | +$4.90K |
| 2023-02-06 | Martin A. Lehr | Chief Executive Officer | Buy | +5,040 | +$4.90K |
| 2023-01-30 | Martin A. Lehr | Chief Executive Officer | Buy | +7,027 | +$4.90K |
| 2023-01-23 | Martin A. Lehr | Chief Executive Officer | Buy | +6,839 | +$4.90K |
| 2023-01-18 | Martin A. Lehr | Chief Executive Officer | Buy | +6,783 | +$5.00K |
| 2022-12-19 | Jennifer Lynn Minai-Azary | Chief Financial Officer | Buy | +25,000 | +$18.50K |
| 2022-12-19 | Martin A. Lehr | Chief Executive Officer | Buy | +20,000 | +$14.80K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Martin A. Lehr | Chief Executive Officer | 1,079,891 | $259.07K |
| Alex C. Levit | Chief Legal Officer, Corp. Sec | 81,983 | $19.67K |
| Jennifer Lynn Minai-Azary | Chief Financial Officer | 80,010 | $19.19K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CNTX quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.